Avidea’s polymer-drug conjugate (PDC) platforms are fueling a pipeline of differentiated assets.
SVC101 is Avidea’s candidate for treating HPV+ cancers. SVC101 comprises Avidea’s SNAPvax cancer vaccine (CV) platform codelivering HPV E6 & E7 antigens and TLR-7/8 agonists (adjuvants) in nanoparticles that target antigen-presenting cells that prime cytotoxic T cell responses. SVC101 is being advanced to Phase 1/2a clinical testing for treating patients with HPV+ cancers with recurrent diseases, and in the neoadjuvant and adjuvant setting.
SNAPvax CV is Avidea’s antigen-specific platform for cancer treatment and provides the advantages of priming >5-fold higher breadth of T cell responses as compared with competing platforms and enabling repeat administration by the intravenous route to engage all stages of the cancer immunity cycle.
SYN001 comprises Avidea’s syntholytic platform delivering a TLR-7/8a (“Syntholytic-TLR-7/8a”) and is being advanced to Phase 1/2a clinical testing for treating patients with advanced solid tumors.
Syntholytic is Avidea’s antigen agnostic platform for treating cancers that lack validated antigens. Syntholytic comprises a virus-sized synthetic nanoparticle with high densities of immunostimulants (or other drugs) and uses dual responsive properties to enable selective drug accumulation and release in tumors following IV administration, thereby improving the therapeutic index of promising drugs that are otherwise hampered by dose-limiting toxicities.
SVT201 is Avidea’s candidate for treating multiple sclerosis (MS). SVT201 comprises Avidea’s SNAPvax tolerance vaccine (TV) platform codelivering all major myelin antigens and an immunomodulator in nanoparticles that target tolerogenic antigen presenting cells that prime regulatory T cell (Treg) responses that suppress / prevent inflammation. SVT201 is being advanced to Phase 1/2a clinical testing for treating patients with progressive and relapse remitting MS.
SNAPvax TV is Avidea’s antigen-specific platform for promoting tolerance for treating autoimmunity. SNAPvax TV provides the advantage that multiple autoantigens and immunosuppressive drugs can be codelivered in nanoparticles of precise size and composition that are optimized for targeting tolerogenic antigen presenting cells.
SNAPvax antibody vaccine (AV) is used for focusing antibody responses against specific epitopes, “minimal immunogens,” when precise antibody responses are required.
The SNAPvax AV platform comprises one or more unique minimal immunogens on the surface of self-assembling nanoparticles further comprising a universal CD4 epitope and TLR-7/8 agonist (adjuvant). Minimal immunogen array enables B cell receptor cross-linking for optimal antibody production.
Discovery phase studies ongoing with VRC, NIH and Duke Human Vaccine Institute.
*Note: SNAPvax AV is rapidly manufacturable using fully synthetic, automated processes and is stable > 3 months in solution at room temperature. This provides a lower cost and more scalable alternative to RNA as a rapid, on-demand vaccine technology.